Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
05/2003
05/02/2003EP1305322A2 Derivatives of branched-chain lipophilic molecules and uses thereof
05/02/2003EP1305319A1 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
05/02/2003EP1305313A1 Fused heterocyclic derivatives as phosphodiesterase inhibitors
05/02/2003EP1305306A2 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
05/02/2003EP1305294A2 Imidazolyl derivatives
05/02/2003EP1305293A1 Hexahydro-7-imino-1h-azepin-2-yl-hexanoic acid derivatives as inhibitors of inducible nitric oxide synthase
05/02/2003EP1305286A2 Cyclopentanoindoles, compositions containing such compounds and methods of treatment
05/02/2003EP1305285A1 N-substituted indoles useful in the treatment of diabetes
05/02/2003EP1305057A1 Microparticulate biomaterial composition for medical use
05/02/2003EP1305024A1 Method for treating fibrotic diseases or other indications ic
05/02/2003EP1223966B1 Use of gdnf for treating corneal defects
05/02/2003EP1196167A4 Method of reducing neuronal injury or apoptosis
05/02/2003EP1185516B1 Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect
05/02/2003EP1119351B1 Use of catechol derivatives as proteinase inhibitors
05/02/2003EP1070058B1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
05/02/2003EP1056454B1 Use of macrolide compounds for treating glaucoma
05/02/2003EP1037886B1 Triazine angiogenesis inhibitors
05/02/2003EP0929578B1 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
05/02/2003EP0802983B1 Expression of urokinase plasminogen activator inhibitors
05/02/2003EP0777483B1 Methods and means for drug administration
05/02/2003EP0772592B1 1H-INDOLE-1-FUNCTIONAL sPLA 2 INHIBITORS
05/02/2003CA2411011A1 5-heteroatom-substituted pyrazoles
05/02/2003CA2410466A1 Hydrazinyl and nitrogen oxide pyrazoles
05/02/2003CA2410364A1 5-heterocyclo-pyrazoles
05/01/2003WO2003035687A1 Nogo receptor homologues and their use
05/01/2003WO2003035679A2 Molecules
05/01/2003WO2003035654A1 Phosphonic acid compounds as inhibitors of serine proteases
05/01/2003WO2003035653A1 Pyridothienopyrimidine compound and salt thereof
05/01/2003WO2003035650A1 Entry inhibitor
05/01/2003WO2003035644A1 Benzimidazole derivatives and their use as kdr protein kinase inhibitors
05/01/2003WO2003035640A1 Pyrimidone compounds and pharmaceutical compositions containing the same
05/01/2003WO2003035638A1 4-imidazolin-2-one compounds
05/01/2003WO2003035635A1 6-hydroxy isoflavones, derivatives and medicaments involving same
05/01/2003WO2003035626A2 Azole derivatives and pharmaceutical compositions containing them
05/01/2003WO2003035621A1 Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
05/01/2003WO2003035599A1 Quarternary ammonium compounds and their use as antimuscarinic agents
05/01/2003WO2003035178A1 Methods and compositions for modulating alpha adrenergic receptor activity
05/01/2003WO2003035109A1 Remedies for pruritus
05/01/2003WO2003035075A1 Inhibitors of human phosphatidyl-inositol 3-kinase delta
05/01/2003WO2003035065A1 Benzimidazoles and analogues and their use as protein kinases inhibitors
05/01/2003WO2003035064A1 Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
05/01/2003WO2003035036A1 Montelukast granule formulation
05/01/2003WO2003035008A2 Functionalized stilbene derivatives as improved vascular targeting agents
05/01/2003WO2003035005A2 Heteroindanes: a new class of potent cannabimimetic ligands
05/01/2003WO2003020283A3 Method for treating diabetic retinopathy
05/01/2003WO2002090352A3 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
05/01/2003WO2002089615A3 Anti-ige antibody to treat ocular allergies
05/01/2003WO2002083712A3 Transporters and ion channels
05/01/2003WO2002081513A3 Disease-associated protein
05/01/2003WO2002078681A3 Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac
05/01/2003WO2002076438A3 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
05/01/2003WO2002074806A3 New interferon beta-like molecules
05/01/2003WO2002048148A3 Pyrazolopyridine derivatives
05/01/2003WO2002005830A3 Extracts from crassulacean acid metabolism (cam) mechanism plants and uses thereof
05/01/2003US20030083505 Benzenedicarboxylic acid derivatives
05/01/2003US20030083378 Comprises 4-(6-acetyl-3-(3-((4-acetyl-3-hydroxy-2-propylphenyl)thio)propoxy)-2 -propylphenoxy)butyric acid for its selective leukotriene antagonist activity
05/01/2003US20030083345 Method of treatment and/or prevention of brain, spinal or nerve injury
05/01/2003US20030083344 Tryptase inhibitors
05/01/2003US20030083343 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
05/01/2003US20030083254 Heparanase-like proteins and nucleotides that encode them
05/01/2003US20030083246 Methods for treating rheumatic diseases using a soluble CTLA4 molecule
05/01/2003US20030082643 Human monoclonal antibodies to FC alpha receptor (CD89)
05/01/2003US20030082554 Nucleotide sequences coding polypeptide for use in the treatment of immunlological, thyroid, metabolic, bone and pancreatic disorders
05/01/2003US20030082171 Deafness therapy, prevention; mylein protein vaccine
05/01/2003US20030082159 Lentiviral vector-mediated gene transfer and uses thereof
05/01/2003CA2466813A1 Benzimidazole derivatives and their use as kdr protein kinase inhibitors
05/01/2003CA2464593A1 6-hydroxy isoflavones, derivatives and medicaments involving same
05/01/2003CA2464111A1 Phosphonic acid compounds as inhibitors of serine proteases
05/01/2003CA2463902A1 Functionalized stilbene derivatives as improved vascular targeting agents
05/01/2003CA2463282A1 Therapeutical agent for pruritus
05/01/2003CA2463101A1 Azole derivatives and pharmaceutical compositions containing them
04/2003
04/30/2003CN1414965A Sulfonamides and derivatives thereof that modulate the activeity of endothelin
04/30/2003CN1414961A Substituted oximes and hydrazones as neurokinin antagonists
04/30/2003CN1414958A Nonpeptide substituted benzothiazepines as vasopressin antagonists
04/30/2003CN1414950A Substituted pyrrole Mannich bases to treating paint and allergic reactions
04/30/2003CN1414859A Combinations for treatment of DNA viral infections
04/30/2003CN1107058C Subsitituted isoxazoles for treatment of inflammation
04/30/2003CN1106842C Usage of glutathione accelerator in preparating medicine for treating macular degeneration
04/29/2003US6555700 1,3-propane diol esters and ethers and methods for their use in drug delivery
04/29/2003US6555675 Dinucleoside polyphosphates which facilitate secretory mechanisms, i.e. increasing the hydration of mucus secretions, stimulating the production of mucins and increasing ciliary beat frequency to facilitate clearance
04/29/2003US6555667 Hypoxia-regulated genes
04/29/2003US6555582 Eye treatments using synthetic thyroid hormone compositions
04/29/2003US6555575 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease
04/29/2003US6555566 Methods and materials for treating and preventing inflammation of mucosal tissue
04/29/2003US6555542 Sulfonamide lactam inhibitors of FXa and method
04/29/2003US6555540 Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
04/29/2003US6555526 Trehalos; Sjogren syndrome.
04/29/2003US6555519 O-glucosylated benzamide SGLT2 inhibitors and method
04/29/2003US6555518 2',2'-difluoronucleosides for suppressing rejection of transplants in mammals; for treatment of autoimmune diseases
04/29/2003US6555377 Process for production of mammalian cell lines
04/29/2003US6555105 Method of treatment with a RANTES antagonist polypeptide
04/29/2003CA2181172C Storage-stable prostaglandin compositions
04/26/2003CA2409084A1 Anti-inflammatory agent and foods and drinks containing the same
04/24/2003WO2003033696A1 Vegf antisense compound
04/24/2003WO2003033671A2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
04/24/2003WO2003033527A2 Cyclosporine analogue mixtures and their use as immunomodulating agents
04/24/2003WO2003033483A1 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
04/24/2003WO2003033482A1 Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors
04/24/2003WO2003033478A1 Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors
04/24/2003WO2003033466A1 Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same
1 ... 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 ... 531